SEC Filing Summary
Entity and period: The supplied filing is OmniLit Acquisition Corp.’s Form 10-K for the fiscal year ended December 31, 2021, signed April 1, 2022. It is not a Syntec Optics Holdings, Inc. operating-company 10-K; Syntec Optics is discussed as a business associated with OmniLit’s CEO. The financial reporting period runs from OmniLit’s May 20, 2021 inception through December 31, 2021.
Business context
OmniLit was a newly formed blank-check company (SPAC) seeking a business combination. It had not selected a target or begun substantive discussions with one by year-end. Its stated focus was advanced manufacturing, particularly optics and photonics, with a targeted enterprise value of approximately $350 million to $750 million.
Financial results and liquidity
| Metric | Reported amount |
|---|---|
| Operating revenue | None; OmniLit had not commenced operating activities. |
| Formation and operating costs | $171,167 |
| Interest income | $1,679 |
| Net loss | $169,488; basic and diluted loss per share was $0.01. |
| Cash used in operating activities | $274,017 |
| Cash outside the trust account | $494,599 at December 31, 2021. |
| Trust investments | $146,626,679 at December 31, 2021, including reported interest; funds were principally reserved for a business combination or required redemptions. |
| Total assets / total liabilities | $147,428,222 / $5,235,345. Liabilities included $5,031,250 of deferred underwriting fees payable only if a business combination closes. |
| Debt | No long-term debt reported. A $300,000 sponsor loan used for IPO expenses was repaid at the IPO closing. |
OmniLit raised $143.75 million in its November 2021 IPO and $6.92 million through private placement warrants. It placed $146.625 million in the trust account. No operating margins are meaningful because the company had no operating revenue. There is no prior comparable-year operating period in the filing.
Material changes and unusual items
- The IPO closed November 12, 2021, with the underwriters’ over-allotment option fully exercised. The public units were sold for $10 each.
- Public Class A shares are redeemable and reported as temporary equity at $146.625 million, or $10.20 per share. The resulting redemption-value accounting contributed to a reported stockholders’ deficit of $4.432 million.
- IPO transaction costs were $8.333 million, including $2.875 million of paid underwriting fees, $5.031 million of deferred fees, and approximately $426,885 of other offering costs.
- The filing reports no material change to risk factors previously disclosed in the IPO prospectus. It also reports no material litigation, off-balance-sheet financing arrangements, or long-term contractual obligations apart from the deferred underwriting fee.
Outlook, risks, and contingencies
- OmniLit had 15 months from the IPO closing to complete a business combination, with two potential three-month extensions, for up to 21 months total. The audit report describes a scheduled liquidation date of February 12, 2023; extension requires the specified sponsor funding and, according to the filing, a letter of intent to acquire or combine with a viable candidate.
- If no transaction is completed within the permitted period, OmniLit must redeem public shares and liquidate. The sponsor is not obligated to fund an extension. The filing says public stockholders would not vote on or redeem shares solely in connection with an extension.
- Management expected available working capital to cover needs through the earlier of a business combination or one year from filing, and disclosed a sponsor commitment letter for up to $100,000 of additional working capital. Actual search and diligence costs could exceed estimates; additional financing may be needed to complete a transaction or meet redemption-related needs.
- Trust funds may be exposed to creditor claims. The sponsor agreed to indemnify certain claims that reduce trust value below specified levels, but OmniLit had not verified the sponsor’s ability to pay and said the sponsor’s only assets were Company securities.
- Management noted that COVID-19 could adversely affect the Company’s financial position or target search, but the impact was not readily determinable. No adjustment was recorded for this uncertainty.
- Potential conflicts include sponsor and management ownership of founder shares and warrants, outside fiduciary or contractual obligations to present opportunities elsewhere, and possible post-combination management or consulting fees. The filing also describes limited controls over expense reimbursements beyond quarterly audit committee review.
- Management concluded disclosure controls were effective at December 31, 2021. The 10-K did not include management’s internal-control-over-financial-reporting assessment or an auditor attestation because of the transition rules for newly public companies. The auditor issued an unqualified opinion on the financial statements, not an opinion on internal controls.
Important facts for investors to verify
- Confirm the issuer: the filing is for OmniLit Acquisition Corp., not Syntec Optics Holdings, Inc.; do not treat OmniLit’s SPAC financials as Syntec’s operating results.
- Check subsequent filings for whether OmniLit identified or completed a business combination, extended its deadline, or liquidated.
- Review the trust balance, redemption terms, deferred underwriting fee, and any changes in the number of public shares or warrants.
- Assess potential dilution and conflicts, including founder-share conversion provisions, warrants, extension funding, and any sponsor or management compensation arrangements.
- Confirm available operating cash and any later financing, since trust assets were restricted and the reported cash outside the trust was $494,599.